AI drug discovery is shifting focus from tool-makers to real-world users—two healthcare stocks show how companies are turning algorithms into actual medicines.

What happened: Eli Lilly and Twist Bioscience are using AI in drug development in different ways. Lilly partners with OpenAI on drug discovery and has built an AI co-innovation lab with Nvidia to find molecules faster; Twist makes synthetic DNA that drugmakers test, and is now integrated into Amazon's new Bio Discovery platform for AI-driven drug design.

Why it matters: The first wave of AI rewarded companies that sold the tools. The next wave appears to reward companies that apply those tools in clinics, labs, and pharmacies to produce new medicines. Both firms show how AI adoption is moving into real-world use rather than staying at the software level.

What to watch: Eli Lilly's recently approved weight-loss pill Foundayo is a near-term growth driver because a pill format (replacing injections) could reach a much larger patient population. Twist reported revenue rising 19% to $110.7 million（約180億円） in fiscal Q2 2026 and has posted 13 straight quarters of rising revenue, though it currently operates at a net loss.